Chorioamnionitis alters the response to surfactant in preterm infants

J Pediatr. 2010 Jan;156(1):10-15.e1. doi: 10.1016/j.jpeds.2009.07.044.

Abstract

Objective: To study the association between antenatal exposure to chorioamnionitis and the neonatal response to surfactant.

Study design: Prospective observational cohort of 301 preterm infants of gestational age < or = 32.0 weeks, 146 of whom received surfactant according to standardized criteria. Fraction of inspired oxygen (FiO(2)) requirement (using analysis of variance) and time to extubation (using Kaplan-Meier and Cox regression analyses) were compared between groups based on the presence of histological chorioamnionitis (HC) with or without fetal involvement (HC-, n = 88; HC + F-, n = 25; HC + F+, n = 33) and between infants who developed bronchopulmonary dysplasia (BPD) or died (n = 57) and BPD-free survivors (n = 89). Multiple logistic regression was performed to investigate the association between HC and BPD.

Results: Compared with HC- infants, HC + F+ infants had significantly greater FiO(2) requirement and prolonged time to extubation postsurfactant, not accounted for by differences in gestational age and birth weight. Infants with BPD/death had a strikingly similar pattern of increased FiO(2) requirement postsurfactant. Moreover, in infants who received surfactant, HC + F+ status was associated with increased risk for BPD (odds ratio [OR] = 3.40; 95% confidence interval [CI] = 1.02-11.3; P = .047) and for BPD/death (OR = 2.72; 95% CI = 1.00-7.42; P = .049).

Conclusions: An impaired surfactant response was observed in preterm infants with severe chorioamnionitis and may be involved in the association between chorioamnionitis, mechanical ventilation, and the development of BPD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biological Products / therapeutic use*
  • Bronchopulmonary Dysplasia / epidemiology
  • Bronchopulmonary Dysplasia / prevention & control
  • Chorioamnionitis / epidemiology*
  • Comorbidity
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Logistic Models
  • Pregnancy
  • Prospective Studies
  • Pulmonary Surfactants / therapeutic use*
  • Respiration, Artificial
  • Respiratory Distress Syndrome, Newborn / epidemiology*

Substances

  • Biological Products
  • Pulmonary Surfactants
  • beractant